AstraZeneca Plc's COVID-19 vaccine is effective against Delta and Kappa variants, which were first identified in India, the company said on Tuesday, citing a study.
The study by the Oxford University investigated the ability of monoclonal antibodies in blood from recovered people and from those vaccinated to neutralize the Delta and Kappa variants, the statement said.
Last week, an analysis by the Public Health England (PHE) showed that vaccines made by Pfizer Inc and AstraZeneca offer high protection of more than 90% against hospitalization from the Delta variant.
The latest Oxford study results are built on the recent analysis by PHE, the company said.
The Delta variant is becoming the globally dominant version of the disease, the World Health Organization's chief scientist said on Friday.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled" Covishield Side Effects: Doctors' Group Urges Centre To Review All Covid Vaccines Windows Computers Lead To 'Blue Screen Of Death' Due To CrowdStrike Error In 1st Statement After Outage, CrowdStrike CEO Says... Massive Worldwide Microsoft Outage: Flights, Markets, Stock Exchange Down Top Joint EMBA Programmes As Per QS Executive MBA Rankings 2024 Centre Issues Advisory On Microsoft Windows Outage Woman Says Jindal Group Executive Groped Her On Flight, Naveen Jindal Reacts Track Latest News Live on NDTV.com and get news updates from India and around the world.